U.S. flag

An official website of the United States government

Here’s how you know
Here’s how you know

**Official websites use .gov**
A **.gov** website belongs to an official government organization in the United States.

**Secure .gov websites use HTTPS**
A **lock** ( A locked padlock) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Search Query:
			MAIN MENU

																				
              Health Topics
								All Health Topics A-Z
					
													
		

		Asthma


				

															Heart-Healthy Living


				

															High Blood Pressure


				

															Sickle Cell Disease


				

															Sleep Apnea


				

															Information & Resources on COVID-19
																				
              Health Education
								Education Programs and Initiatives
					
													
		

		The Heart Truth®


				

															Learn More Breathe Better®


				

															Blood Diseases and Disorders Education Program


				

															Publications and Resources
																				
              The Science
								Research Focus Areas
					
													
		

		Blood Disorders and Blood Safety


				

															Sleep Science and Sleep Disorders


				

															Lung Diseases


				

															Health Disparities and Inequities


				

															Heart and Vascular Diseases


				

															Precision Medicine Activities


				

															Obesity, Nutrition, and Physical Activity


				

															Population and Epidemiology Studies


				

															Women’s Health


				

															Research Topics


				

															Clinical Trials


				

															All Science A-Z
																				
              Grants and Training
								Grants and Training Home


				

															Policies and Guidelines


				

															Funding Opportunities and Contacts


				

															Training and Career Development
																				
              News and Events
								News and Events Home
					
													
		

		Email Alerts


				

															All News
					
													
		

		NHLBI News


				

															NHLBI in the Press


				

															Research Features


				

															All Events
					
													
		

		Past Events


				

															Upcoming Events
																				
              About NHLBI
								About NHLBI Home
					
													
		

		Mission and Strategic Vision


				

															Leadership


				

															Divisions, Offices and Centers


				

															Advisory Committees


				

															Budget and Legislative Information


				

															Jobs and Working at the NHLBI


				

															Contact and FAQs


				

															NIH Sleep Research Plan
						
						HOME
		Search Text: Home/About the NHLBI/Divisions, Offices and Centers/< Back ToDivision of Intramural Research/Critical Care Medicine and Pulmonary Branch

Critical Care Medicine and Pulmonary Branch
                    
                                                                                            Stewart Levine, M.D.
				Acting Branch Chief
				
            levines@nhlbi.nih.gov
                        The Critical Care Medicine and Pulmonary Branch conducts clinically oriented research into diseases and disorders affecting the lungs and respiratory tract. The spectrum of research spans from molecular and cell based investigation to bedside and population based studies. The Branch also provides clinical pulmonary physiologic testing, consultative and advanced bronchoscopic services and offers specialty research training of pulmonary and critical care clinical fellows.
            

                        Our Labs
                    
Applied Precision Omics
    For children and adults with advanced lung diseases, transplantation is often the only treatment. Unfortunately, half of these patients will die within 5 – 6 years after transplant because of transplant rejection. Transplant rejection is detected by analyzing a biopsy of the transplanted organ. Obtaining biopsy samples requires anesthesia and is quite an invasive procedure. Additionally, biopsy has low sensitivity and usually picks up rejection at late stages when treatments options are limited and often with limited benefits. Could early detection and treatment of rejection save the transplanted organ from rejection? The focus of APO is to investigate whether early detection and treatment of rejection improves transplant survival.
        
            Contact:
    Sean Agbor-Enoh
                            M.D., Ph.D.
                            Lasker Clinical Tenure-Track Investigator
                            sean.agbor-enoh@nih.gov
                                                                                                
        Asthma and Lung Inflammation
    Asthma affects approximately 8% of the U.S. population with significant associated morbidity and mortality. Despite recent advances, there is an ongoing need to develop new treatments for severe asthmatics who do not respond to current therapies (Please see this video to learn more how asthma affects patients who are participating in clinical asthma research at NIH: https://www.youtube.com/watch?v=jVUZLcZwyxk). To address this clinical problem, the Laboratory of Asthma and Lung Inflammation has identified novel roles for apolipoproteins and lipoprotein receptors in modifying airway inflammation, airway remodeling, and airway hyperreactivity in asthma. Furthermore, by defining new mechanisms that modify asthma pathobiology, our laboratory has identified novel treatment approaches that are currently being advanced to clinical trials so that we can begin to assess their safety and effectiveness for asthma.
        
            Contact:
    Stewart Levine
                            M.D.
                            Senior Investigator
                            levines@nhlbi.nih.gov
                                                                                                
        Basic and Translational Immunology
    The Laboratory of Basic and Translational Immunology, led by Dr. Parizad Torabi-Parizi, focuses on understanding innate immune cell and effector T cell behavior in peripheral tissues, mechanisms regulating such behavior.
        
            Contact:
    Parizad Torabi-Parizi
                            M.D.
                            Tenure Track Investigator
                            parizad.torabi-parizi@nih.gov
                            301-496-6597
                                                                                                
        Chronic Airway Infection
    The Laboratory of Chronic Airway Infection, led by Dr. Kevin Fennelly, focuses on bronchiectasis, a condition that damages the body's ability to clear mucus from the airways and increases risk of severe lung infections by nontuberculous mycobacteria (NTM), which commonly are found in wet environments such as streams, rivers, and marshes. People with inflammatory lung disease such as cystic fibrosis are particularly vulnerable to this condition. Dr. Fennelly hopes to contribute to reducing the impact of such infections by studying common genetic characteristics of the people who suffer from them, defining how the infections lead to disease, and ultimately developing more effective, efficient treatments. Dr. Fennelly and his collaborators also seek to address potential genetic risk loci that might explain overlapping characteristics of health conditions such as cystic fibrosis, primary ciliary dyskinesia, connective tissue disorders including Marfan or Ehlers-Danlos syndromes, and immune-related disorders.
        
            Contact:
    Kevin Fennelly
                            M.D., M.P.H.
                            Senior Research Clinician
                            kevin.fennelly@nih.gov
                                                                                                
        Pulmonary Function Lab
    Many disease processes and therapies may impact the respiratory system.  Pulmonary function testing employs a wide variety of tests to assess the function and response of the respiratory system.  This enables characterization of baseline status of the system as well as longitudinal measurement of changes related to disease progression, improvement,  and response to or adverse effects from therapies.  Testing modalities employed in the laboratory include spirometry, plethysmography, nitrogen washout, diffusion capacity, cardiopulmonary exercise testing, walk testing, respiratory muscle strength, high altitude simulation, shunt studies, impulse oscillometry, bronchoprovocation, and exhaled nitric oxide analysis.  Customized tests may be developed with investigators as required.
        
            Contact:
    Andrew Lipton
                            M.S., M.D., MPH and TM
                            Medical Director
                            andrew.lipton@nih.gov
                                                                                                
        Pulmonary Vascular Biology Laboratory
    The focus of the Pulmonary Vascular Biology Lab, led by Dr. Jason Elinoff, is the interplay between lung vascular endothelium and immune effector cells and their contributions to the development and progression of pulmonary arterial hypertension (PAH).
        
            Contact:
    Jason Elinoff
                            M.D.
                            Tenure Track Investigator
                            elinoffj@mail.nih.gov
                            301-402-4846
                                                                                                
        Translational Research
    The Laboratory of Translational Research, led by Dr. Joel Moss, focuses on clinical and translational areas of investigation. Primary clinical and translational studies address the pathogenesis and treatment of cystic lung diseases, such as lymphangioleiomyomatosis (LAM). Studies of LAM focus on the growth, genetics and metastasis, or spreading, of LAM cells, which is responsible for destruction of the lung parenchyma. Basic studies examine the post-translational modification of proteins by ADP-ribosylation, both that catalyzed by bacterial toxins involved in disease as well as the reversible ADP-ribosylation cycle endogenous to human cells, which participates in membrane repair and response to oxidative stress.
        
            Contact:
    Joel Moss
                            M.D., Ph.D.
                            Senior Investigator
                            mossj@nhlbi.nih.gov
                                                                                                
        NHLBI Pulmonary Training Opportunities
    NIH/NHLBI Track University of Maryland Pulmonary and Critical Care Fellowship Program Back To Top Link
  

        

        Back to top
  Web Policies & Notices
  

        

              Accessibility
                      No FEAR Act Data
                      Privacy Policy
                      Freedom of Information Act (FOIA)
                      HHS Vulnerability Disclosure
    
          Related Government Websites
  

        

              Health and Human Services
                      National Institutes of Health
                      Office of the Inspector General
                      USA.gov
    
          Stay Connected
    
      
            chat bubblesLive ChatLive Chat with us, Monday through Friday, 8:30 a.m. to 5:00 p.m. EST.envelopeGet Email AlertsReceive automatic alerts about NHLBI related news and highlights from across the Institute.
  Footer Bottom
  

        



Contact Us
                            Site Index
                            Jobs